The latest price target for Puma Biotechnology (NASDAQ:PBYI) was reported by HC Wainwright & Co. on November 20, 2024. The analyst firm set a price target for $7.00 expecting PBYI to rise to within 12 months (a possible 131.02% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Puma Biotechnology (NASDAQ:PBYI) was provided by HC Wainwright & Co., and Puma Biotechnology reiterated their buy rating.

There is no last upgrade for Puma Biotechnology

There is no last downgrade for Puma Biotechnology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Puma Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Puma Biotechnology was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Puma Biotechnology (PBYI) rating was a reiterated with a price target of $7.00 to $7.00. The current price Puma Biotechnology (PBYI) is trading at is $3.03, which is out of the analyst’s predicted range.